Buckanovich R J, Yang Y Y, Darnell R B
Laboratory of Molecular Neuro-Oncology, Rockefeller University, New York, New York 10021, USA.
J Neurosci. 1996 Feb 1;16(3):1114-22. doi: 10.1523/JNEUROSCI.16-03-01114.1996.
Nova-1, a protein expressed in tumors and neurons, is a target antigen in a human paraneoplastic motor disorder [paraneoplastic opsoclonus-myoclonus ataxia (POMA)]. We evaluated the relationship between the function of Nova-1 and its role as a disease antigen. We show that Nova-1 is a neuron-specific RNA-binding protein with sequence and functional similarities to FMR-1. Nova-1 mRNA is restricted to the subcortical nervous system, and the protein binds to RNA with high affinity. Nova-1 KH domains mediate this RNA binding, and point mutations within them abrogate binding. POMA disease antisera (6/6) recognize the third KH domain but not an inactive point mutant, and affinity-purified antibody blocks Nova-1 RNA binding. Thus, a cardinal feature of POMA is the production of antibodies that inhibit Nova-1-RNA interactions, suggesting such inhibition may cause the neurological disease.
Nova-1是一种在肿瘤和神经元中表达的蛋白质,是人类副肿瘤性运动障碍[副肿瘤性眼阵挛-肌阵挛性共济失调(POMA)]中的一种靶抗原。我们评估了Nova-1的功能与其作为疾病抗原的作用之间的关系。我们发现Nova-1是一种神经元特异性RNA结合蛋白,在序列和功能上与FMR-1相似。Nova-1 mRNA局限于皮质下神经系统,该蛋白质以高亲和力结合RNA。Nova-1的KH结构域介导这种RNA结合,其中的点突变会消除结合。POMA疾病抗血清(6/6)识别第三个KH结构域,但不识别无活性的点突变体,亲和纯化的抗体可阻断Nova-1与RNA的结合。因此,POMA的一个主要特征是产生抑制Nova-1与RNA相互作用的抗体,这表明这种抑制可能导致神经系统疾病。